... WhatsApp

New Chemotherapy Combination May Improve Outcomes Before Pancreatic Cancer Surgery

You are here >> Home > Latest Updates > GI & HPB > Pancreas Cancer >New Chemotherapy…

Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma randomised, open-labeDOI 10.

Pancreatic cancer is often treated with chemotherapy before surgery to shrink the tumor and increase the chances of removing it completely. Two common treatment combinations are mFOLFIRINOX and a newer regimen called PAXG.

A large international clinical trial studied 260 patients with stage I–III pancreatic cancer that could potentially be removed with surgery. Patients received either mFOLFIRINOX or PAXG for four months before surgery.
The results showed that PAXG controlled the cancer for a longer time before major events like tumor growth, recurrence, or death occurred. On average, patients receiving PAXG had about 16 months before disease-related events, compared with about 10 months for those receiving mFOLFIRINOX.

Side effects were common with both treatments, which is expected with strong chemotherapy. Around two-thirds of patients in each group experienced significant side effects, but the overall safety of the treatments was similar.
These findings suggest that PAXG may become a new standard chemotherapy option before surgery for patients with resectable or borderline resectable pancreatic cancer. Researchers will continue to follow patients to see how these treatments affect long-term survival.
For patients facing pancreatic cancer surgery, this study offers encouraging news that newer treatment strategies may improve outcomes.

Rate this post
Robotic Cancer Surgery